After 3 years of testing, the Capri device has just presented its results at the 2020 congress of the American Society of Clinical Oncology (ASCO). And the results are positive!
What is Capri exactly? Behind these five letters (CAncérologie Parcours de santé region Île-de-France) hides an innovative telemedicine system set up at the Gustave Roussy Institute (94).
Concretely, the Capri program adds personalized follow-up to “traditional” appointments with the oncologist: the patient has access to an online platform (on phone, tablet or computer) to ask questions relating to disease or report the onset of adverse effects. A team of nurses (specially trained and in contact with oncologists) then quickly recontact the patient for referral without waiting for the next appointment with the doctor … which is sometimes several weeks or months away!
A device that adds to the traditional monitoring of cancer patients
At the Institut Gustave Roussy, 600 cancer patients treated with oral chemotherapy were drawn: half of them were able to test the Capri program while the other half benefited from ‘traditional monitoring.
Verdict? In patients benefiting from the Capri program, a reduction in side effects (27% in the Capri group compared to 37% in the conventional group), fewer hospitalizations (23% instead of 32%) and fewer emergency room visits (15 % instead of 22%) were observed.
At present, the Capri device is only intended for patients treated with oral chemotherapy. “Capri it’s not over, notes Dr. Olivier Mir, head of the outpatient department at the Institut Gustave Roussy. Other developments are planned, with specific types of cancer, or even in patients on hormone therapy. “
Source:Gustave Roussy Institute
Read also :
- Cancer screening reportedly dropped by 50% due to the Covid-19 health crisis
- Dogs sniff for breast cancer
- 2 out of 3 cancers will be cured by the end of the decade
- A blood test to detect cancer? Research is progressing!